Literature DB >> 10779741

Cutting edge: CD4 is not required for the functional activity of IL-16.

N L Mathy1, N Bannert, S G Norley, R Kurth.   

Abstract

IL-16 functions as a chemoattractant factor, inhibitor of HIV replication, and inducer of proinflammatory cytokine production. Previous studies have suggested that CD4 is the receptor for IL-16, because only CD4+ cells respond to IL-16 and both the anti-CD4 Ab OKT4 and soluble CD4 can block IL-16 function. However, these are only indirect evidence of a requirement for CD4, and to date a direct interaction between IL-16 and CD4 has not been shown. In this paper, we report that cells from CD4 knockout mice are as responsive to IL-16 as their CD4 wild-type equivalents in both assays testing for IL-16 function (chemotaxis and production of proinflammatory cytokines). In addition, the inhibitory effect of soluble CD4 on IL-16 function observed using CD4 wild type murine cells was not observed using CD4 knockout cells. These data demonstrate that CD4 is not required for IL-16 function and suggest that another molecule acts as the major receptor.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10779741     DOI: 10.4049/jimmunol.164.9.4429

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

1.  Human and mouse mast cells use the tetraspanin CD9 as an alternate interleukin-16 receptor.

Authors:  Jian C Qi; Jing Wang; Sravan Mandadi; Kumiko Tanaka; Basil D Roufogalis; Michele C Madigan; Kenneth Lai; Feng Yan; Beng H Chong; Richard L Stevens; Steven A Krilis
Journal:  Blood       Date:  2005-09-06       Impact factor: 22.113

2.  Increased expression of IL-16 in inflammatory bowel disease.

Authors:  D Seegert; P Rosenstiel; H Pfahler; P Pfefferkorn; S Nikolaus; S Schreiber
Journal:  Gut       Date:  2001-03       Impact factor: 23.059

3.  Transient elevation of interleukin-16 levels at the initial stage of meningitis in children.

Authors:  T Suzuki; A Ishiguro; T Shimbo
Journal:  Clin Exp Immunol       Date:  2003-03       Impact factor: 4.330

4.  Human mid-gestation amniotic fluid contains interleukin-16 bioactivity.

Authors:  Catherine A Thornton; Judith A Holloway; Janis K Shute; John W Holloway; Norma D Diaper; John O Warner
Journal:  Immunology       Date:  2009-04       Impact factor: 7.397

5.  The intermediate-conductance calcium-activated potassium channel KCa3.1 contributes to atherogenesis in mice and humans.

Authors:  Kazuyoshi Toyama; Heike Wulff; K George Chandy; Philippe Azam; Girija Raman; Takashi Saito; Yoshimasa Fujiwara; David L Mattson; Satarupa Das; James E Melvin; Phillip F Pratt; Ossama A Hatoum; David D Gutterman; David R Harder; Hiroto Miura
Journal:  J Clin Invest       Date:  2008-09       Impact factor: 14.808

6.  Ablation of the CD9 receptor in human lung cancer cells using CRISPR/Cas alters migration to chemoattractants including IL-16.

Authors:  David J Blake; Jonathon D Martiszus; Tia H Lone; Steven D Fenster
Journal:  Cytokine       Date:  2018-06-05       Impact factor: 3.861

7.  Cytokine-neuroantigen fusion proteins as a new class of tolerogenic, therapeutic vaccines for treatment of inflammatory demyelinating disease in rodent models of multiple sclerosis.

Authors:  Mark D Mannie; J Lori Blanchfield; S M Touhidul Islam; Derek J Abbott
Journal:  Front Immunol       Date:  2012-08-20       Impact factor: 7.561

8.  Expression of interleukin-16 by tumor-associated macrophages/activated microglia in high-grade astrocytic brain tumors.

Authors:  Markus Liebrich; Liang-Hao Guo; Hermann J Schluesener; Jan M Schwab; Klaus Dietz; Bernd E Will; Richard Meyermann
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2007 Jan-Feb       Impact factor: 4.291

9.  Direct interaction of immunoglobulins with synovial fibroblasts: a missing link in the pathogenesis of rheumatoid arthritis?

Authors:  Thomas Pap
Journal:  Arthritis Res Ther       Date:  2004-12-20       Impact factor: 5.156

10.  Protective Role of the MER Tyrosine Kinase via Efferocytosis in Rheumatoid Arthritis Models.

Authors:  Claire E J Waterborg; Silke Beermann; Mathijs G A Broeren; Miranda B Bennink; Marije I Koenders; Peter L E M van Lent; Wim B van den Berg; Peter M van der Kraan; Fons A J van de Loo
Journal:  Front Immunol       Date:  2018-04-13       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.